Biond Biologics

Company Overview

Snapshot

Founded in April 2016 by Tehila Ben Moshe and Ori Shilo, Biond Biologics operates with 11–50 employees. The company has raised $45 million across 4 funding rounds from 7 investors. In June 2026, Biond Biologics appointed Giovanni Selvaggi as Chief Medical Officer.

Business overview

Biond Biologics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company utilizes biologics that target novel immune evasion mechanisms, identified through in-house research using real-world patient and tumor samples. Additionally, Biond Biologics is advancing an intracellular delivery platform designed to enable biologics, such as antibodies or enzymes, to access and drug intracellular targets previously considered "undruggable." The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In June 2026, Biond Biologics announced the appointment of Giovanni Selvaggi as Chief Medical Officer. This strategic leadership addition signals the company's commitment to strengthening its clinical development capabilities and advancing its pipeline of immunotherapies, which is crucial for a clinical-stage biopharmaceutical company aiming to bring novel treatments to market.

Company Intelligence Q&A

What was a significant recent leadership appointment at Biond Biologics?

In June 2026, Biond Biologics appointed Giovanni Selvaggi, MD, as Chief Medical Officer (CMO). This appointment is expected to bolster the company's clinical development and strategic direction.

What was the most recent funding activity for Biond Biologics?

In June 2026, Biond Biologics closed an investment and collaboration with Guangzhou Sino-Israel Biotech Investment Fund (GIBF).

When did Biond Biologics initiate a Phase 2 study for BND-22?

In October 2025, Biond Biologics announced the initiation of a Phase 2 study for BND-22 in combination with anti-PD-1 therapy, marking a significant step in its clinical development.

When did Biond Biologics announce the closing of its Series C financing?

In November 2021, Biond Biologics announced the closing of its Series C financing, with participation from investors including.

When did Biond Biologics enter into a global licensing agreement with Sanofi?

In January 2021, Biond Biologics and Sanofi entered into a global licensing agreement for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor.